News in Numbers

The UK National Health Service (NHS) is set to receive a £29bn ($39.1bn) funding boost, reflecting a 3% annual rise on current levels over the next three years to reach £226bn by 2029.

The global atopic dermatitis (AD) market is poised to reach $22.4bn in drug sales within the decade, buoyed by the availability of targeted therapies, as per GlobalData analysis.

Merck & Co’s (MSD) antibody drug conjugate (ADC) zilovertamab vedotin has demonstrated an objective response rate (ORR) of 56.3% in treating diffuse large B-cell lymphoma.

SCHOTT Pharma is investing more than €100m ($114m) to expand its manufacturing capacity for sterile ready-to-use (RTU) cartridges at its site in Lukácsháza, Hungary.

The US Food and Drug Administration (FDA) has rejected Stealth BioTherapeutics’ elamipretide for the treatment of Barth syndrome after 16.5-month review.